A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence

Trial Profile

A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs SER 262 (Primary)
  • Indications Clostridium infections
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Seres Therapeutics
  • Most Recent Events

    • 03 Aug 2017 According to a Seres Therapeutics media release, top-line data from this trial is expected in early 2018.
    • 16 Mar 2017 According to a Seres Therapeutics media release, results from this trial are expected in the second half of 2017.
    • 11 Aug 2016 According to a Seres Therapeutics media release, results are expected in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top